Swedbank AB Sells 3,055 Shares of Natera, Inc. $NTRA

Key Points

• Swedbank AB reduced its stake in Natera, Inc. by 6.8% in the second quarter, holding 42,080 shares valued at $7.11 million after selling 3,055 shares.
• Insider transactions included Director Rowan E. Chapman and CEO Steven Leonard Chapman selling a combined total of 7,829 shares, reflecting declines in their ownership stakes of 31.37% and 3.10%, respectively.
• Natera's stock opened at $181.11, with recent earnings showing a revenue of $546.60 million but missing EPS estimates at ($0.74), leading to a negative net margin of 12.89%.

Swedbank AB decreased its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 6.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,080 shares of the medical research company's stock after selling 3,055 shares during the quarter. Swedbank AB's holdings in Natera were worth $7,109,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of NTRA. Quantinno Capital Management LP bought a new position in Natera in the 4th quarter valued at about $373,000. Focus Partners Advisor Solutions LLC bought a new position in Natera in the 4th quarter valued at about $227,000. Forum Financial Management LP bought a new position in Natera in the 4th quarter valued at about $327,000. Mackenzie Financial Corp increased its holdings in Natera by 33.9% in the 4th quarter. Mackenzie Financial Corp now owns 4,317 shares of the medical research company's stock valued at $683,000 after buying an additional 1,092 shares during the period. Finally, Polar Asset Management Partners Inc. increased its holdings in Natera by 1.6% in the 4th quarter. Polar Asset Management Partners Inc. now owns 96,105 shares of the medical research company's stock valued at $15,213,000 after buying an additional 1,500 shares during the period. 99.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on NTRA shares. Stephens reissued an "overweight" rating and issued a $183.00 target price on shares of Natera in a report on Friday, August 15th. Morgan Stanley reaffirmed an "overweight" rating and set a $195.00 price target on shares of Natera in a report on Sunday, August 10th. Barclays reaffirmed an "overweight" rating and set a $210.00 price target (up from $190.00) on shares of Natera in a report on Friday, August 8th. Piper Sandler reaffirmed an "overweight" rating and set a $220.00 price target (up from $210.00) on shares of Natera in a report on Monday, August 11th. Finally, Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the company an "outperform" rating in a report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $192.88.

Natera Stock Down 1.1%

Shares of NASDAQ NTRA traded down $1.92 during midday trading on Monday, reaching $179.19. The stock had a trading volume of 1,414,145 shares, compared to its average volume of 891,184. Natera, Inc. has a twelve month low of $117.27 and a twelve month high of $183.00. The company's 50 day moving average price is $157.22 and its 200 day moving average price is $155.46.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same quarter last year, the firm posted ($0.30) EPS. The firm's revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Equities analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 6,092 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $139.81, for a total transaction of $851,722.52. Following the transaction, the chief executive officer owned 169,400 shares in the company, valued at $23,683,814. The trade was a 3.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gail Boxer Marcus sold 4,299 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total transaction of $719,480.64. Following the transaction, the director owned 8,118 shares in the company, valued at $1,358,628.48. The trade was a 34.62% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,423 shares of company stock worth $8,459,656 over the last ninety days. 5.63% of the stock is owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.